Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2022.11.035 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The effect of meloxicam at the time of treatment of hoof-horn lameness in pasture-grazing dairy cattle on time to lameness soundness, pregnancy risk and time to conception; a randomized control trial.
J Dairy Sci
January 2025
Boehringer-Ingelheim Animal Health, Level 2, 3 Te Kehu Way, Mount Wellington, Auckland, New Zealand.
The aims of this study were to assess the effect of meloxicam at the time of lameness treatment for hoof-horn (HH) lesions in dairy cattle on 1) time to lameness soundness post trimming and block application and 2) reproductive success Five seasonal-calving pasture-based dairy farms located in the Waikato region of New Zealand were enrolled into a randomized clinical interventional trial. Farmers were tasked with identifying lame animals over a period of approximately -4 to 6 weeks relative to the herd start of mating (HSM), with lameness subsequently confirmed with lameness score (LS) by trained technicians (0-3 scale, where ≥2 are considered lame). Animals with a LS ≥2 were examined by a veterinarian who then enrolled animals if they presented lame with HH (white-line or sole) lesions.
View Article and Find Full Text PDFWhat's Eating You? Hookworm and Cutaneous Larva Migrans.
Cutis
November 2024
Dr. Bloomquist is from the School of Medicine, University of South Carolina, Columbia. Dr. Elston is from the Department of Dermatology & Dermatologic Surgery, Medical University of South Carolina, Charleston.
Hookworm infection represents a major global disease burden, in terms of both morbidity and economic impact, and there has been a resurgence of hookworms in developed nations where these parasites were once thought to be eradicated. Hookworms can infest humans or other mammals as their primary hosts depending on the species. The 2 most common species that seek human hosts-Necator americanus and Ancylostoma duodenale-enter the body through the epidermis, and hookworm infection may manifest as a pruritic and papular inflammatory reaction know as ground itch.
View Article and Find Full Text PDFAnaphylaxis in pediatric patients: single-center study in a private hospital.
Allergol Immunopathol (Madr)
January 2025
Division of Allergy and Clinical Immunology, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.
This study aimed to characterize the profile of probable anaphylaxis cases treated at a private pediatric hospital emergency department in São Paulo. It investigated triggering factors, the presence of cofactors, treatments administered, and follow-up for these cases through interviews with the patients' families. A single-center cross-sectional study analyzed medical records of children and adolescents treated between 2016 and 2020.
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
Washington University in St. Louis, School of Medicine, St. Louis, MO, USA; Washington University School of Medicine, St. Louis, MO, USA; Knight Alzheimer Disease Research Center, St. Louis, MO, USA.
Although amyloid b immunotherapies offer great potential for prevention or delay of symptoms in dominantly inherited AD (DIAD), the mechanism of action of this class of medications does not address the underlying mechanism of most DIAD mutations. Moreover, the need for repeated IV infusions or sub-cutaneous injections with Ab immunotherapies may prove challenging for long-term prevention approaches. The majority of DIAD mutations appear to affect the interaction of the gamma-secretase enzyme with the Amyloid Precursor Protein (APP) making this enzyme an attractive target for disease modification.
View Article and Find Full Text PDFThe modern use of hydroxyurea for children with sickle cell anemia.
Haematologica
January 2025
Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati OH; University of Cincinnati College of Medicine, Cincinnati OH; Global Health Center, Cincinnati Children's Hospital Medical Center, Cincinnati OH.
Over the past 40 years, the introduction and refinement of hydroxyurea therapy has led to remarkable progress for the care of individuals with sickle cell anemia (SCA). From initial small proof-of-principle studies to multi-center Phase 3 controlled clinical trials and then numerous open-label studies, the consistent benefits of once-daily oral hydroxyurea have been demonstrated across the lifespan. Elevated fetal hemoglobin (HbF) serves as the most important treatment response, as HbF delays sickle hemoglobin polymerization and reduces erythrocyte sickling.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!